Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : sees currencies supporting 2019 outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/14/2019 | 06:57am EDT
A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt

FRANKFURT (Reuters) - Germany's Merck KGaA, which is taking over U.S. electronic chemicals maker Versum Materials, said it expected a slight tailwind from foreign exchange effects supporting earnings growth this year.

Merck on Tuesday confirmed its guidance for an underlying increase of 10-13% in 2019 earnings before interest, taxes, depreciation and amortisation (EBITDA) and adjusted for one-off items but now sees a positive effect of 0% to +2% from currencies.

It had previously seen a 3-4% drag from foreign exchange effects.

First-quarter EBITDA, adjusted for special items, slipped 4% to 929 million euros (806 million pounds), below the average analyst estimate of 944 million in a Reuters poll.

Stocks mentioned in the article
ChangeLast1st jan.
MERCK KGAA 0.78% 90.64 Delayed Quote.0.73%
VERSUM MATERIALS INC 0.12% 51.31 Delayed Quote.85.10%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
05/21MERCK : EMD Serono, Inc - GLUCOPHAGE Notification to HCPs and Patients
AQ
05/21MERCK : MilliporeSigma Joins TRANSVAC2 Program to Advance Vaccine Development an..
AQ
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/20MERCK : MilliporeSigma Joins TRANSVAC2 Program to Advance Vaccine Development an..
PU
05/17Pfizer, Merck KGaA clinch needed approval for Bavencio, directly competing ag..
AQ
05/16MERCK KGAA : retools F-star pact, walks away from lead PD-L1 drug
AQ
05/15MERCK KGAA : Notification and public disclosure of transactions by persons
EQ
05/15NEWS HIGHLIGHTS : Top Company News of the Day
DJ
05/15NEWS HIGHLIGHTS : Top Company News of the Day
DJ
05/15NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (€)
Sales 2019 15 511 M
EBIT 2019 2 633 M
Net income 2019 1 532 M
Debt 2019 4 992 M
Yield 2019 1,46%
P/E ratio 2019 24,76
P/E ratio 2020 20,76
EV / Sales 2019 1,08x
EV / Sales 2020 0,93x
Capitalization 11 715 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 104 €
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA0.73%13 123
WUXI APPTEC CO LTD6.48%13 311
KYOWA HAKKO KIRIN CO LTD3.26%10 338
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD21.04%9 171
JAZZ PHARMACEUTICALS PLC10.33%7 749
YUHAN CORP--.--%2 705